Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13357777 | 0.86 | GPR119 (0.48) | GPR119CYP2C9KCNH2PIK3CD | |
| SCHEMBL3240385 | 0.85 | PIK3CD (0.53) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL288503 | 0.85 | GPR119 (0.57) | GPR119CYP2C9KCNH2 | |
| SCHEMBL288925 | 0.85 | GPR119 (0.46) | GPR119CYP2C9PIK3CD | |
| SCHEMBL20375400 | 0.84 | GPR119 (0.41) | GPR119CYP2C9KCNH2PIK3CDPIK3CA | |
| SCHEMBL13733200 | 0.83 | GPR119 (0.44) | GPR119CYP2C9 | |
| SCHEMBL3258302 | 0.83 | GPR119 (0.47) | GPR119CYP2C9KCNH2PIK3CD | |
| SCHEMBL12281328 | 0.82 | ACACB (0.36) | GPR119CYP2C9KCNH2PIK3CDPIK3CA | |
| SCHEMBL1449593 | 0.77 | PAK1 (0.43) | — | |
| SCHEMBL3252437 | 0.76 | EGFR (0.36) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382204-B1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | MERCK SHARP & DOHME (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-1732562-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006083491-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |